By EBELE ONUORAH
The first -ever country’s indigenous grown natural product, Ciklavit ,use in the management of Sickle Cell Disorder, has recorded impressive indicators following the breaking of the study code by clinical trailists at one of the research institutes in Ghana, endorsed and certified by the World Health Organisation (WHO) for clinical studies in Africa.
At the code breaking meeting in Accra, Ghana, the studies were reviewed to ascertain patents’ characteristics, biochemical profile and statistical deductions.
It could be recalled that in 2000, a multi- centre clinical trails were conducted across University research centres in Nigeria to validate the findings of the manufacturers, Neimeth International Pharmaceuticals Plc. It was then, discovered that Ciklavit caused a significant reduction in frequency and intensity of painful crisis in test subjects. There was also a significant reduction in liver size in the test subjects.
The study also showed that the product improved the osmotic fragility and hence the deformability of the red blood cells in sickle cell anaemia, thus exhibiting some beneficial effort on the frequency of vasocclusive crisis in the study.
A press statement signed by Neimeth’s Head, Corporate Affairs, Mr. O Nwaka, stated that in the study, Ciklavit reduced total circulating white blood cells, which might be due to the reductions of inflammatory mediators and reduced plasmal level of liver enzymes and phosphates.
“At the 56th session of WHO regional committee meeting held in Addis Ababa Ethopia in 2006, Ciklavit was presented and endorsed by the world body. Ciklavit has bagged the Orient Sickle Cell Trust Foundation award in 2006. Neimeth’s vision for Ciklavit is so significant that plans have reached advanced stages to formulate the product in solid forms to enhance compliance and also as drops to take care of toddlers,” he noted.